Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Quentin, Giordan"'
Autor:
Quentin Giordan, Julia Salleron, Catherine Vallance, Clothilde Moriana, Christelle Clement-Duchene
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
BackgroundThe use of antibiotics (ATB) and proton-pump inhibitors (PPI) alters the composition and diversity of the gut microbiota, which can influence the immune system, consequently interfering with response to anti-PD1 immune checkpoint inhibitors
Externí odkaz:
https://doaj.org/article/fbba6673a8e249ae9fc9a300ee6ca2dc
Autor:
Laurence, Schenone, Caroline, Houillier, Marie Laure, Tanguy, Sylvain, Choquet, Kossi, Agbetiafa, Hervé, Ghesquières, Gandhi, Damaj, Anna, Schmitt, Krimo, Bouabdallah, Guido, Ahle, Remy, Gressin, Jérôme, Cornillon, Roch, Houot, Jean-Pierre, Marolleau, Luc-Matthieu, Fornecker, Olivier, Chinot, Frédéric, Peyrade, Reda, Bouabdallah, Cécile, Moluçon-Chabrot, Emmanuel, Gyan, Adrien, Chauchet, Olivier, Casasnovas, Lucie, Oberic, Vincent, Delwail, Julie, Abraham, Virginie, Roland, Agathe, Waultier-Rascalou, Lise, Willems, Franck, Morschhauser, Michel, Fabbro, Renata, Ursu, Catherine, Thieblemont, Fabrice, Jardin, Adrian, Tempescul, Denis, Malaise, Valérie, Touitou, Lucia, Nichelli, Magali, Le Garff-Tavernier, Aurélie, Plessier, Philippe, Bourget, Caroline, Bonmati, Sophie, Wantz-Mézières, Quentin, Giordan, Véronique, Dorvaux, Cyril, Charron, Waliyde, Jabeur, Khê, Hoang-Xuan, Luc, Taillandier, Carole, Soussain, Thomas, Gastinne
Publikováno v:
Bone marrow transplantation. 57(6)
We analysed the therapeutic outcomes of all consecutive patients with primary central nervous system lymphoma (PCNSL) registered in the prospective French database for PCNSL and treated with intensive chemotherapy (IC) followed by autologous stem cel
Autor:
Julia Salleron, Catherine Vallance, Quentin Giordan, Christelle Clement-Duchene, Clothilde Moriana
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology
Frontiers in Immunology
BackgroundThe use of antibiotics (ATB) and proton-pump inhibitors (PPI) alters the composition and diversity of the gut microbiota, which can influence the immune system, consequently interfering with response to anti-PD1 immune checkpoint inhibitors